CSIMarket Company Name, Ticker, Suppliers, else..
 
Stemtech Corporation  (STEK)
Other Ticker:  
 
 
Price: $0.0245 $0.00 -0.163%
Day's High: $0.0245 Week Perf: -5.77 %
Day's Low: $ 0.02 30 Day Perf: -40.96 %
Volume (M): 0 52 Wk High: $ 0.07
Volume (M$): $ 0 52 Wk Avg: $0.04
Open: $0.02 52 Wk Low: $0.01



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 117
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Stemtech Corporation
Stemtech Corporation is a global biotechnology company that focuses on stem cell research and development. They specialize in producing supplements that support adult stem cell renewal and regenerative processes in the body. Stemtech's products are formulated using natural ingredients and are designed to enhance overall health and wellness. The company is dedicated to advancing stem cell science and providing innovative solutions for optimal cellular health.


   Company Address: 4851 Tamiami Trail North Naples 34103 FL
   Company Phone Number: 715-6000   Stock Exchange / Ticker: STEK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.04%    
GILD        0.88% 
ILMN   -2.24%    
REGN   -3.26%    
VRTX        3.97% 
• View Complete Report
   



Stemtech Corporation

Stemtech Corporation's Revenue Surges, but Profit Margins Fall Short in First Quarter of 2024



Pharmacy Services & Retail Drugstore company, Stemtech Corporation, released its financial report for the first quarter of 2024. While the company boasted a remarkable surge in revenue of 23.406% to $1.38 million compared to the same reporting period last year, the financial picture painted by the report suggests a concerning situation. As we dig deeper, it becomes evident that Stemtech Corporation's losses have compounded and its performance in the market has been far from satisfactory. This article aims to analyze the underlying issues and shed light on the reasons behind the company's bearish outlook.
Lackluster Financial Performance:
Despite the surge in revenue, Stemtech Corporation suffered a loss of $-0.02 per share in the first quarter of 2024. This represents a decline from the previous year's loss of $-0.01 per share, indicating a deepening financial crisis. Moreover, the company's net loss for the financial interval ending March 31, 2024, stood at $-1.421 million, a substantial increase from the $-2.237 million deficit reported in the same period last year. Such consistent losses raise concerns about Stemtech Corporation's ability to turn its business around and achieve sustainable profitability.
Stemtech Corporation

Stemtech Corporation Sets New Benchmark with Exceptional Fiscal Performance in the Third Quarter ending September 30, 2023



Pharmacy Services & Retail Drugstore company, Stemtech Corporation, recently announced its financial results for the third quarter of 2023. The company experienced a remarkable surge in revenue, but also posted a shortfall per stock, raising questions about the potential impact of these results on the company's future.
Revenue Surge Outshines Competitors:
In the July to September 30, 2023 reporting period, Stemtech Corporation witnessed a notable 26.426% increase in revenue, reaching $1.30 million compared to the corresponding quarter from the previous year. This growth rate exceeded that of its competitors within the Pharmacy Services & Retail Drugstore sector, as most companies saw their business advance by 9.85% in the same period.
Stemtech Corporation

Stemtech Corporation Defies the Odds with Remarkable Resurgence in Revenue during Challenging Times



Stemtech Corporation, a company operating in the [relevant industry], has experienced significant fluctuations in its share prices over the last five trading days. With a downward trend of -7.21%, the company's shares now reflect a year-to-date performance decrease of -48.52%. These figures suggest a challenging period for Stemtech, raising questions about the future implications for the company.
1. Break-even in Q2 2023:
During the fiscal second quarter of 2023, Stemtech Corporation reached a break-even point of $0.00 per share, a significant improvement compared to the previous year's loss of $-0.56 per share. However, compared to the prior quarter's loss of $-0.04 per share, there seems to be a minimal improvement. This break-even situation indicates that Stemtech is making efforts to improve its financial performance.
Stemtech Corporation

Stemtech Corporation's Revenue Plummets Amidst Weak Demand, Raising Alarms for Investors

Stemtech Corporation is a biotech company that focuses on developing and commercializing products that enhance health and wellness through stem cell nutrition. The company offers various supplements and skincare products that claim to improve overall health and wellness.
However, the company has recently suffered a setback due to weak demand for its products, which led to a decline in revenue and increased losses for the most recent fiscal period. The net loss per share increased to $-0.04 from $-0.01, with revenue going down by -20.12% to $1.12 million. This decline in revenue has been a cause of concern for investors and stakeholders of the company.






Stemtech's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com